

## Special Issue

# (Virus-Like) Particles as Platforms for Vaccine Delivery and Modulation of Immune Cell Function

### Message from the Guest Editor

Our immune system preferentially discriminates between self and non-self antigens, thus contributing to long-term homeostasis. Some antigens are introduced in a (water-)soluble form into our body. In contrast, other antigens are part of a smaller or larger particulate context, such as virus particles, bacteria, or even larger microorganisms. On the one hand, it may be interesting to induce potent effector and memory functions. In contrast, on the other hand, immune responses may be directed towards regulatory responses. Since the (virus-like) particles themselves can be varied not only in size and physicochemical composition but also in the way they express nominal antigens and transport them to the host organisms, they are ideally suited for the delivery of vaccine antigens and as platforms for triggering immunoregulatory responses. We encourage all scientists interested in research based on (virus-like) particles and immunomodulation to submit their manuscripts for this Special Issue of *Vaccines* and guarantee expert and timely peer review.

### Guest Editor

Dr. Winfried F. Pickl

Institute of Immunology, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Lazarettgasse 19, 1090 Vienna, Austria

### Deadline for manuscript submissions

closed (31 May 2025)



## Vaccines

an Open Access Journal  
by MDPI

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/208105](https://mdpi.com/si/208105)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).